@MarkC53916729 During initial partnership CC, CA praised $JNJ capabilities (and how they’re uniquely suited to meet $ARWR objectives). $JNJ closely eyes their revenue stream. There’s ongoing patent expirations &amp; biosimilar intrusion~it’s inevitable, RNAi is the future revenue wellspring for BP.